Chief Medical Officer of Health Dr. Deena Hinshaw confirmed a death linked to vaccine-induced immune thrombotic thrombocytopenia (VITT) in a woman in her 50s after receiving the AstraZeneca vaccine
“As chief medical officer of health, I am sad to report that tonight we have confirmed the death of an Alberta woman in her 50’s from VITT following vaccination from the AstraZeneca vaccine,” said Hinshaw late Tuesday night.
The Alberta case marks the second VITT case and only death related to VITT out of more than 253,000 doses of AstraZeneca or CoviSHIELD/AstraZeneca that have been administered in Alberta to date.
“While any death is tragic, it is important to remember that the risks of dying or suffering other severe outcomes from COVID-19 remain far greater than the risk following AstraZeneca vaccine,” said Hinshaw.
The global frequency of VITT has been estimated at approximately one case in 100,000 to 250,000 doses of vaccine. In comparison, Albertans 50 to 59 who are diagnosed with COVID-19 are 350 times more likely to die from that infection than to experience VITT after an AstraZeneca vaccine. They are also at least 1,500 times more likely to be hospitalized from COVID-19 than experiencing VITT after getting AstraZeneca.